Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol

Next Previous
Trial Profile

ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 07 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aviptadil (Primary)
  • Indications COVID-19 respiratory infection
  • Focus Expanded access; Therapeutic Use
  • Acronyms SAMICARE
  • Sponsors APR Applied Pharma Research; NeuroRX; NRx Pharmaceuticals

Most Recent Events

  • 19 Jul 2022 Status changed from recruiting to completed.
  • 27 Sep 2021 Results presented in NRx Pharmaceuticals media release.
  • 16 Jun 2021 According to a Relief Therapeutics media release, EAP data are being submitted by NRx to the U.S. Food and Drug Administration (FDA) as "real world" evidence in support of the findings from the phase 2b/3 trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top